I believed, and continue to believe, that the market missed the GOOD news of today's announcement, which dramatically improves NWBO's balance sheet. The $4 price doesn't hurt either.
Then I looked at the new July 2013 presentation on the company's website (under the "ABOUT US" tab). If your time is limited, just look at slide 3 and imagine the possibilities. This company is unreal!
I agree. We know by the actions of NWBO management, Linda Powers having $20M back in stock when she converted the debt, Cognate sees the volume of vaccines being manufactured every month and where they are going and we know in smaller trials the vaccine works as noted in ovarian, GBM, prostate and now with more potent DC the market is looking at NWBO for tangible results in larger trial IMO.
In Q3 and Q4 catalyst due, with GBM interim results and update on DCVax-Direct on patients with inoperable tumors with very little hope for survival.....just imagine what could happen to the stock price "IF" vaccine has tumor regression let alone complete remission of the tumors???
This is where the market will finally take notice of this $110M company which is considerably undervalued with only 30M shares OS and late stage international Phase III GBM trial in the homestretch to results in 2014. I personally believe in their vaccine being a game changer and I guess we will find out soon.
Would also like to add that manufacturing often gets overlooked while evaluating a biotech because it isn't as "sexy" as discussing the science behind the cure. It, however, can be the deciding factor in the scalability of the cure. NWBO has done a LOT of hard, painstaking work on this front, in both the US and Europe. Once we begin to have milestones being reached, I think the achievements in the manufacturing side of the company will come more and more into focus by serious investors and would be a big positive for the company.
Well, sort of. Cognate will know if additional batches are required. The first batch provides enough for a 3 year course. Difficult for us to know how enrollment has been split before and after the hiatus, but one would assume a number of re-orders has taken place. This would provide them some confidence in the recent deal.